Author: admin

  • Prolonged sitting may raise blood clot risk in young people: Experts

    Prolonged sitting may raise blood clot risk in young people: Experts

    New Delhi: Prolonged sitting while gaming, binge-watching OTT content or attending online classes may increase the risk of blood clots in the legs among young people, vascular specialists have warned, citing evidence linking sedentary behaviour to a higher risk of venous thromboembolism (VTE).

    The experts said extended periods of uninterrupted sitting can slow blood flow from the legs and contribute to deep vein thrombosis (DVT), a condition in which a clot forms in the deep veins and can become life-threatening if it travels to the lungs.

    The warning was issued at the VSI-ASVS 2026 conference, being held at Pullman and Novotel, Aerocity, here from October 8 to 10.

    The conference has brought together more than 400 faculty members and over 1,000 delegates from India and abroad to discuss advances and emerging challenges in vascular and endovascular surgery.

    A 2024 systematic review and dose-response meta-analysis published in Scientific Reports, which included 25 articles and 31 studies, found that people with the highest levels of sedentary behaviour had approximately 24 per cent higher risk of VTE than those with the lowest exposure.

    The analysis also reported a 2 per cent increase in risk for every additional hour of sedentary behaviour per day.

    Dr Tapish Sahu, Organising Secretary of VSI-ASVS 2026 and Director and Head of the Department of Vascular and Endovascular Surgery at Max Hospital Delhi, said doctors were increasingly seeing young patients whose lifestyle habits, including prolonged sitting and excessive screen exposure, warranted closer attention.

    “We are increasingly seeing young patients in our OPD with symptoms that make us look closely at their lifestyle, including prolonged sitting, excessive screen exposure and long gaming sessions. The latest evidence is concerning because the risk is not restricted to people who are completely inactive,” Dr Sahu said.

    The 2024 meta-analysis found about a 24 per cent higher risk of VTE among those with the highest sedentary exposure, while every additional hour of sedentary behaviour was associated with approximately a 2 per cent increase in VTE risk, Dr Sahu said.

    When a young person sits continuously for four, five or six hours playing games or binge-watching OTT content, the calf muscles are barely working as a pump for venous blood, he explained.

    “We need to make movement breaks a part of digital life,” he said.

    DVT, which was traditionally associated with older age, hospitalisation or prolonged bed rest, can also affect younger people.

    Experts, however, cautioned that screen use does not automatically cause blood clots and prolonged sitting is generally an additional risk factor, particularly when combined with obesity, dehydration, smoking, hormonal factors, inherited clotting disorders or a previous history of thrombosis.

    A study examining adolescents with thrombosis identified 11 patients who reported at least four hours of daily screen exposure. Their average digital-device use was around six hours a day, while uninterrupted immobility averaged 2.7 hours. Eight had DVT in the lower limbs, two had pulmonary embolism and one had subclavian-vein thrombosis.

    Researchers also identified inherited thrombophilia in many of these patients, suggesting that prolonged digital-device use and immobility may act as additional triggers rather than the sole cause of thrombosis.

    Dr Tarun Grover, Organising Chairman of VSI-ASVS 2026 and Senior Director of Peripheral Vascular and Endovascular Sciences at Medanta, said doctors needed to ask young patients about their screen-time habits while assessing vascular health.

    “Earlier, when we thought about prolonged immobility, we primarily discussed long-distance travel, hospitalisation or being bedridden. Today, we also need to ask young patients how many hours they spend continuously sitting in front of a gaming console, computer or OTT screen.

    “The evidence showing a 24 per cent higher VTE risk with higher sedentary exposure should make us take this issue seriously. A young age should not create a false sense of security, particularly when prolonged sitting is combined with other risk factors,” he said.

    Dr Bhupesh Garg, Senior Vascular and Endovascular Surgeon at the Vascular Society of India, said prolonged sitting and smoking could contribute to vascular risks through different mechanisms.

    “Just as smoking increases vascular and clotting risks, prolonged sitting can also increase the risk of blood clots, although through a different mechanism. When a person remains seated for hours, the calf-muscle pump becomes inactive, venous blood flow from the legs slows down and blood can stagnate in the deep veins.

    “This is particularly concerning when young people spend several uninterrupted hours gaming or binge-watching OTT content. We are seeing more young patients in clinical practice in whom prolonged sedentary behaviour is an important part of the lifestyle history. The message should be simple: if you are going to spend hours on a screen, do not spend those hours completely still,” he said.

    Doctors said young people often spend several hours sitting in school or college before continuing with gaming, social media, streaming or other online activities, leaving little scope for movement throughout the day.

    They advised people to break up long periods of sitting with regular movement and avoid remaining immobile for hours at a stretch. They also stressed that physical activity alone may not completely offset the risks associated with prolonged sedentary behaviour.

    The experts said the comparison between sitting and smoking should be understood as a public-health warning, not a claim that the two carry equivalent risks. They urged greater awareness of sedentary behaviour as a potentially modifiable factor in vascular health.

    • Published On Oct 10, 2026 at 07:51 AM IST

    Join the community of 2M+ industry professionals.

    Subscribe to Newsletter to get latest insights & analysis in your inbox.

    All about ETHealthworld industry right on your smartphone!

  • UP rolls out single shot iron injection to fight anaemia-linked maternal deaths

    UP rolls out single shot iron injection to fight anaemia-linked maternal deaths

    Shailvee Sharda

    Lucknow: Strengthening efforts to cut preventable maternal and newborn deaths, the Uttar Pradesh health department has rolled out one-shot iron injections to tackle anaemia among pregnant women.

    Mission director, National Health Mission (NHM), UP, Pinky Jowel said the decision followed a successful pilot across five districts—Sitapur, Hardoi, Rae Bareli, Jalaun and Bahraich. The intervention is aimed at women who find it difficult to take iron-folic acid (IFA) tablets regularly due to side effects or adherence challenges, and those who require quicker improvement in haemoglobin levels during pregnancy.

    “The one-shot injection is called Ferric Carboxymaltose (FCM) and allows greater compliance of medicine. More than 20,000 doses of the injection were administered in the pilot,” Jowel said on Friday.

    Health officials said FCM can reduce repeated visits to health facilities compared with Iron Sucrose, which often requires multiple sessions to complete a dose course. By delivering treatment in a single sitting, the injection is expected to ease access for women in rural and hard-to-reach areas and improve continuity of care.

    Buoyed by the response to the pilot, the department has placed the injection on the state’s essential medicines list. Officials said the step would help streamline procurement and ensure availability at public health facilities, alongside training of doctors and staff nurses and awareness-building among beneficiaries.

    Anaemia is a significant factor in maternal mortality that weakens cardiac reserve and erodes immunity. This leaves little strength in women to tolerate blood loss during childbirth, suggests The Missing Evidence: anaemia, postpartum bleeding and maternal death Report brought out by Anaemia Action Alliance formed by WHO and UNICEF.

    Diet and Biomarkers Survey in India (DABS-I) by ICMR–National Institute of Nutrition (NIN) estimates anaemia prevalence among adolescent girls and adult women at 39% to 42%.

    As per Union health ministry’s Anaemia Mukt Bharat operational framework and findings from clinical maternal death audits, anaemia is a direct or indirect contributor to an estimated 40% to 50% of maternal deaths. In Uttar Pradesh, Maternal Death Surveillance and Response (MDSR) records classify severe anaemia as the direct cause in roughly 7% to 19% of cases.

    Hospital reviews have also indicated that more than half of women who died had haemoglobin levels below seven units on admission.

    Join the community of 2M+ industry professionals.

    Subscribe to Newsletter to get latest insights & analysis in your inbox.

    All about ETHealthworld industry right on your smartphone!

  • US measles cases rise to 4,080, CDC says

    US measles cases rise to 4,080, CDC says

    • Published On Oct 10, 2026 at 07:34 AM IST

    Bengaluru: The US CDC on Friday reported 4,080 confirmed measles cases in the country as of October 8, up 193 from a week earlier.

    Twenty-six cases were identified among international visitors, according to the Centers for Disease Control and Prevention

    Measles-related hospitalizations this year stand at 414, or 10% of cases, compared with 244 hospitalizations in 2025

    The CDC has confirmed two measles-associated deaths in 2026, though it has not identified the states involved, compared with three deaths in 2025

    Separately, Pennsylvania health officials have reported five deaths linked to the state’s measles outbreak this year

    Last month, the CDC shifted to using mortality data from the National Center for Health Statistics for measles-related deaths, rather than relying on state health departments, a change that has drawn scrutiny

    As of October 9, the Pennsylvania health department has reported 1,136 measles cases in 2026, including 219 hospitalizations

    Children and teenagers aged 5 to 19 accounted for the largest share of cases at 1,716, or 42% of infections, followed by adults aged 20 and older at 1,635 cases, or 40%

    Earlier this week, New York declared a statewide disaster emergency over a measles outbreak after reporting 108 cases this year through October 3, including 92 cases since July 15

    (Reporting by Siddhi Mahatole and Christy Santhosh in Bengaluru; Editing by Sahal Muhammed)

    • Published On Oct 10, 2026 at 07:34 AM IST

    Join the community of 2M+ industry professionals.

    Subscribe to Newsletter to get latest insights & analysis in your inbox.

    All about ETHealthworld industry right on your smartphone!

  • Blindness treatment based on Nobel-winning research shows promise

    Blindness treatment based on Nobel-winning research shows promise

    New York: Patients with blindness due to retinitis pigmentosa who received a treatment based on research that won the 2026 Nobel Prize in Physiology or Medicine had their ability to detect objects restored in a small trial that demonstrated the potential of the novel approach.

    So-called optogenetic therapy uses light to control brain cells. In the study, researchers combined gene therapy that made surviving retinal ganglion cells sensitive to light with delivery of light to stimulate these cells.

    The 10 trial participants each received an injection into one eye carrying genetic instructions for ChrimsonR, a light-sensitive protein from GenSight Biologics.

    Patients then wore goggles that captured visual information, converted it into patterns of light at wavelengths that activated ChrimsonR in the modified retinal cells, and sent the patterns of light back to the eye.

    Seven patients became more sensitive to light, with six achieving clinically meaningful improvements, such as being able to detect when an object was present, determine where it was located and reach toward it accurately.

    One severe adverse event occurred immediately after injection and resolved within minutes, researchers reported in The New England Journal of Medicine.

    While larger studies are needed to definitively prove the usefulness of ChrimsonR and the goggles, the findings show that even at a very advanced stage of blindness, surviving retinal ganglion cells can be made responsive to light and transmit visual information to the brain, the researchers said.

    “Even in people with profound vision loss, the visual system retains a remarkable capacity to process new information,” study leader Dr. Jose-Alain Sahel of the University of Pittsburgh said in a statement.

    RADIATION EFFECTIVE AS SURGERY FOR LOCALIZED PROSTATE CANCER

    Radiotherapy kept localized prostate cancer under control just as well as surgery, with fewer side effects, researchers reported at the recent American Society for Radiation Oncology, or ASTRO, meeting in Boston.

    After a median of eight years of following patients, survival without recurrence was statistically similar. Of those who received five sessions of stereotactic body radiation therapy delivered over two weeks, 91% were alive without cancer recurrence versus 84% after surgery.

    SBRT delivers the radiation directly to the prostate while limiting exposure to nearby healthy tissue.

    The trial involved 123 patients, most with low- or intermediate-risk cancers who were monitored for reappearance of a tumor or a rise in prostate-specific antigen levels, a potential indicator of prostate cancer.

    The trial’s original goal was to compare quality of life after the interventions. Efforts to enroll nearly twice as many participants were thwarted by the COVID pandemic, leaving the study with too few patients to answer that question.

    Because it was not designed to establish noninferiority for cancer control, the trial cannot prove the treatments are equivalent for this outcome.

    “What we can say is that… we have mature data showing excellent cancer outcomes with five-treatment radiotherapy,” study leader Dr. Nicholas van As of The Royal Marsden NHS Foundation Trust in the UK said in a statement.

    A separate analysis presented at ASTRO found that patient-reported sexual-function scores declined in both groups but remained significantly better after the radiation therapy. Median erectile-function scores on a 25-point scale, where higher scores indicate better function, were 19 with SBRT and 5 for prostatectomy after five years.

    Also at five years, 8.3% of SBRT patients were using urinary pads for leaks, compared with 48% of surgery patients.

    AVOIDING WHOLE-BRAIN RADIATION IN RARE LUNG CANCER

    Patients with an uncommon, aggressive form of lung cancer who develop brain metastases can benefit from a safer radiotherapy technique that is already standard for common lung tumors, according to data from a study reported at ASTRO.

    Stereotactic radiosurgery uses high-dose radiation beams to destroy brain tumors without surgical incisions and with minimal damage to nearby brain tissues.

    It is already the preferred treatment for brain metastases from most other tumors. Small cell lung cancer has been an exception for fear that treating only visible tumors could leave cancer cells behind.

    As a result, patients undergo whole-brain radiation, increasing their risks for memory loss and other cognitive declines.

    In the trial, 151 patients received either stereotactic radiosurgery or a modern form of whole-brain radiation.

    Patients lived a median of 17 months after focused stereotactic radiosurgery versus nine months following whole-brain radiotherapy.

    The trial was designed to assess the length of time before patients experienced cognitive decline from each treatment method. The researchers found no significant difference, possibly because of protection afforded by the newer form of whole-brain radiation, they said.

    Comparisons of cognitive outcomes may also have been complicated by fewer whole-brain radiation patients alive for later follow-up.

    While prolonged survival was not the trial’s primary goal and cannot be proved by this study, the results show how far both approaches have come, principal investigator Dr. Vinai Gondi of the Northwestern Medicine West Region and Proton Center in Warrenville, Illinois, said in a statement.

    “For patients with small cell lung cancer, we now have two modern radiation therapy strategies to consider and randomized evidence to help us understand how best to use them,” Gondi said.

    (To receive the full newsletter in your inbox for free sign up here)

    (Reporting by Nancy Lapid; Editing by Bill Berkrot)

    • Published On Oct 10, 2026 at 07:33 AM IST

    Join the community of 2M+ industry professionals.

    Subscribe to Newsletter to get latest insights & analysis in your inbox.

    All about ETHealthworld industry right on your smartphone!

  • TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

    TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

    Immunology research continues to draw investment for new ways to suppress excessive immune responses. TRexBio takes a different approach, tapping into the body’s built-in way of keeping the immune system in balance. A TRex-discovered molecule is progressing in the clinic in the hands of partner Eli Lilly. Now the biotech has $116.7 million in IPO cash to support clinical development of its wholly owned assets.

    Late Thursday, TRex priced 8.33 million shares at $14 each, which was the low end of the preliminary price range it had set earlier in the week. Those shares began trading on the Nasdaq Friday under the stock symbol “TRXB.”

    The research of South San Francisco-based TRex focuses on regulatory T cells, or Tregs. While the activity of immune cells leads to inflammation, the body counterbalances that with Tregs, which tamp down excessive immune responses and stop the immune system from attacking healthy tissue.

    There are some biotech companies developing Treg cell therapies made by harvesting and engineering a patient’s own Tregs or working with Tregs sourced from healthy donors. While there’s evidence that these approaches can work, the commercialization of T cell therapies for cancer shows the logistical hurdles of engineering cells into living medicines. There’s one FDA-approved Treg so far, a blood cancer treatment developed by Orca Bio. It’s made by shipping a sample of patient blood to an Orca facility that isolates Tregs. Those cells are then shipped back for infusion into the patient. The complexity, cost, and time for manufacturing Treg cell therapies likely limits its use in large autoimmune disease populations, TRex said in its IPO filing.

    Rather than working with directly with Tregs, TRex aims to leverage Tregs already in the patient’s body. Its drugs are fusion proteins designed to activate and expand Tregs that are in inflamed tissue as a way of restoring immune balance. The company says its drugs can do so selectively, without also activating proinflammatory immune cells. These drugs come from a TRex platform technology that gleans immunology insights by analyzing a database of healthy and diseased tissue samples.

    “Our approach is designed to address disease at its source — in the tissue — by developing medicines focused on tissue immune homeostasis that we believe have the potential to provide a durable clinical benefit,” TRex said in the filing.

    TRex formed in 2018. In 2021, Lilly participated in the biotech’s Series A financing. Two years later, the pharma company paid $55 million up front to begin a research collaboration. The alliance produced TRB-051, which is designed to modulate immune effector cells. In June, TRex said Lilly plans to advance TRB-051 to Phase 2a testing in lupus with cutaneous involvement.

    TRex’s most advanced wholly owned program is TRB-061, which is designed to activate tumor necrosis factor receptor 2 (TNFR2), expanding and activating Tregs in inflamed tissues. In August, TRex reported Phase 1a results showing activation and expansion of Tregs in the tissue of healthy volunteers. The study drug was also well tolerated and no serious adverse events were reported. The results supported dose selection for a Phase 1b test in patients with moderate-to-severe atopic dermatitis; preliminary data are expected in mid-2027. TRex also describes alopecia areata as a “priority indication,” pointing to published studies supporting the role of Tregs in mediating the hair follicle cycle and hair regrowth.

    A second TRex drug candidate, TRB-071, is designed to activate the protein CD30 to augment tissue Tregs and block immune system inflammatory signaling. In the filing, TRex points to genetic studies supporting the involvement of CD30 and its ligand in inflammatory bowel disease. The company plans to start a Phase 1 test in the first half of next year.

    In its history as a private company, TRex said it had raised about $220 million. Lilly paid TRex a $15 million milestone payment in 2024 and the biotech is eligible to receive up to $577.5 million more in additional milestone payments, according to the filing. TRex last raised money early this year, a $50 million financing.

    A 2021 collaboration agreement with a Johnson & Johnson affiliate was terminated last year, according to the filing. But the document also shows Johnson & Johnson Innovation—JJDC owns a 4.6% post-IPO stake. Lilly is TRex’s largest shareholder with a 16.8% stake after the IPO, followed by the 14.1% owned by SV Health Investors. TRex said Lilly has expressed an interest in purchasing additional shares at the IPO price in an amount not to exceed 19.9% of the company, but there is no binding commitment for the stock purchase.

    As of the end of the second quarter of this year, TRex reported its cash position was $90.9 million. Combined with the IPO proceeds, TRex plans to spend about $90 million to bring TRB-016 through the readout of topline Phase 2 data in atopic dermatitis and alopecia areata and $10 million for the start and completion of TRB-071’s Phase 1 test in healthy volunteers. The company estimates its capital will last into the second half of 2029.

    Retension Pharma Reels In $45M for Next-Gen Hypertension Drug

    Retension Pharmaceuticals joined the public markets with an IPO that raised $45 million for a drug in clinical development for uncontrolled hypertension.

    Retension’s RTN-001 is a small molecule inhibitor of an enzyme called PDE-5. In its IPO filing, the company notes that first-generation PDE-5 inhibitors, such as the sexual dysfunction drug Viagra, were initially studied in cardiovascular indications such as hypertension and angina. Retension contends these drugs did not offer adequate bioavailability and tissue penetration to address cardiac tissue, leading to their failure as blood pressure medications.

    Falls Church, Virginia-based Retension describes RTN-001 as a next-generation PDE-5 inhibitor engineered for better bioavailability and increased distribution to places such as the aorta and its branches. In two Phase 2 pilot trials, the company said the once-daily pill led to clinically meaningful placebo-adjusted reductions in blood pressure.

    “We believe RTN-001 has the potential to be an effective treatment for hypertension with a favorable safety profile and thus be part of an anti-hypertensive treatment approach,” Retension said in its IPO filing.

    The molecule that is now RTN-001 was originally developed by a company called Surface Logix. It has changed hands several times; in 2023, Retension licensed all rights to the molecule from Redux Therapeutics. As of the end of June, Retension reported its cash position was about $13.5 million. That capital along with the IPO proceeds will go toward clinical development of RTN-001, Retension’s only drug candidate.

    The company plans to spend about $18 million to complete an ongoing Phase 2b test of RTN-001 in uncontrolled hypertension. Preliminary data are expected in the first half of 2027. Another $10 million is budgeted for preparing for a planned Phase 3 test in this indication.

    Retension offered 3.75 million shares priced at $12 each, which was the midpoint of the price range the biotech set in preliminary financial terms earlier in the week. Those shares began trading on the Nasdaq Friday under the stock symbol “RTSN.”

    Public domain image by Flickr user NIH Image Gallery

  • STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds

    STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds

    By Ed Silverman

    Oct. 9, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    The gifts and payments that doctors receive from drugmakers increased inappropriate prescribing and the number of prescriptions written, likely leading to rising health care costs, according to a Cochrane review of dozens of previous studies that have explored the influence the pharmaceutical industry has on medical practice.

    In addition, pharmaceutical advertising or education aimed at doctors may also increase inappropriate prescribing, probably increases the number of prescriptions written, and may increase the costs of prescriptions. But conflict-of-interest policies that restrict or manage interactions between companies and doctors probably improved prescribing practices, the analysis found.

    However, there was not enough evidence to draw clear conclusions on whether free drug samples and other promotions affect decisions to place specific drugs on hospital formularies. These are the list of medicines approved for use and routinely stocked in a hospital or health system.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

    STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

    NIH funding uncertainty thwarts U.S. researchers, Argenx stumbles, and more biotech news

    Close up of an eye
    Adobe

    Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

    Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

    This is the Readout. Please read it.

    And don’t miss us too much Monday, when the newsletter will be paused for the holiday. We’ll be back in your inbox Tuesday.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. Meghana Keshavan covers biotech and contributes to The Readout newsletter.

    2. General Assignment Reporter

      Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

  • STAT+: Up and down the ladder: The latest comings and goings

    STAT+: Up and down the ladder: The latest comings and goings

    By Ed Silverman

    Oct. 9, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

    And here is our regular feature in which we highlight a different person each week. This time around, we note that Q32 Bio hired José Trevejo as chief medical officer. Previously, he worked at Enveda Therapeutics, where he was chief medical officer and head of clinical pipeline strategy.

    But all work and no play can make for a dull chief medical officer.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • What Life Sciences Commercial Teams Can Learn from Digital Health

    What Life Sciences Commercial Teams Can Learn from Digital Health

    A cursory glance across job descriptions at most major pharmaceutical companies will, if one is being unkind, look essentially identical to the 2010s: the same divisional divide of analytics, field, launch, CRM, and content, to name just a few, with essential requirements listing a relevant degree and a set number of years in the subdivision. Meanwhile, AI threatens to upend the commercial ecosystem as we know it, if we let it. There’s no shortage of investment in commercial AI: budgets exist, and pilots launch.  What’s missing is a redefinition of the realm of commercial possibility. R&D teams talk about AI in terms of what’s possible, where Commercial teams mostly talk about it in terms of what’s faster: faster call planning, faster reporting, faster content approval. In the pharmaceutical industry, we’re not pondering what the Commercial function could become, only what it could do quicker. I believe that the pharmaceutical industry could learn several vital lessons from the digital health teams they are so frequently adjacent to, or in partnerships with.

    Today

    As it stands, commercial teams still remain largely siloed, despite a decades-long effort to the contrary: the SWAT teams who swoop in for launch, the marketing teams who focus on a “360-degree view of the customer” and pore over agency data on tactic performance, the sales teams who battle daily for two to five minutes with target HCPs, the digital teams optimizing Veeva or Salesforce and wrangling unwieldy data, and the market access teams negotiating, lobbying, and analyzing. Each function is a separate thread in the complex ball of yarn that is a Commercial team in 2026.  Each trying to grapple with the pace of change driven by AI for specific, single threaded needs. For example, a rep getting handed a new “AI-driven next best action” tool but it’s bolted onto the same static quarterly system that existed before, and doesn’t address any fundamental underlying model improvements.

    Opportunities for Pharma

    The real question: if we designed a pharma commercial function from scratch today, would it look anything like this? My hypothesis is no, and that it would look much closer to the world of digital health.

    Digital health and Pharma remain distant cousins in the family tree of life sciences and health. Where digital health can focus on specific interventions and inventions, Pharma, Big Pharma at least, has the unenviable task of spreading its approach across indications, therapeutic areas, and ultimately entire patient and HCP populations. The result is that digital health companies have grown up leaner, with commercial functions built as a specific, consolidated, and usually much smaller function than in pharma. 

    What pharma commercial could borrow from digital health isn’t complicated or novel, but it isn’t obvious in the day to day of a big pharma juggernaut. I once heard that in the beginning days of the internet, the NY Times typed in the full newspaper – just digitizing the physical copy. This is an exact analogy for how most of big pharma is using agentic AI now: focused on re-creation of existing ways of working and increasing efficiencies.  

    The less obvious side to the speed and efficiency coin is the idea of changing the actual operating rhythm of the portfolio: shipping concepts to production in days rather than months or years. A digital health team ships a feature in weeks based on a usage pattern; a pharma commercial team can spend a quarter just getting requirements gathered. Or radical focus: a digital health commercial function is built around a handful of clear outcomes, not a dozen sub-functions each optimizing their own area. Pairing radical focus with pharma’s strength in regulatory & compliance creates the opportunity to expedite patient outcomes in a way before unseen. Finally, digital health companies build with partners from day one because they have to, while pharma often plans in-house first and partner only once internal options are exhausted, organizational fatigue has taken grip, or the “build” is ready to get going.

    Making It a reality

    What would it look like if Pharma embraced a digital health style way of working? Potentially, it would be by replacing the sprawl of sub-divisional dashboards and systems with one shared data layer, a single source of truth on HCP engagement, patient journeys, tactic performance, and pipeline, with access rights layered on top rather than entirely separate systems per function. Instead of a field force, maybe it’s a cognitive command center AI that operates across functions instead of within one, flagging a stalled account to market access, content, and the field team simultaneously instead of routing sequentially through three approval chains. And rethinking the field model itself: rather than dispersing reps to chase five-minute HCP windows on a static cycle, that same investment could fund fewer, richer touchpoints, twice-yearly events, and deeper partnerships with different, AI native platforms with distribution & reach like OpenEvidence that HCPs are already choosing to use on their own terms.

    None of this requires more commercial budget than pharma is already spending. It requires spending it on reimagining commercial as a function instead of speeding up an existing function. Digital health and pharma have plenty to learn from, and with, each other, and AI is the first real forcing function either industry has had to do it. The Pharma commercial teams that treat this as a chance to redesign the model, not just streamline it, will be the ones that change what’s possible for HCPs and patients. The remainder will only benefit from greater day to day efficiency.

    Source: champpixs, Getty Images

    Suzy Jackson

    Suzy Jackson is a Digital Health & Commercial Pharma subject matter expert and former Digital Health Chief Commercial Officer at RVO Health, as well as former Head of the North America Life Sciences Commercial Consulting team at Accenture. Suzy’s independent advisory focuses on Commercial technology, strategy, Go-To-Market efforts, market entry, partnership shaping, and competitive analysis across Pharma and Consumer Health. Outside of her advisory work, Suzy is an avid scuba diver, traveler, and sits on the Boards of two non-profits focused on women’s rights, legal advocacy, and survivorship from trauma and abuse.

    This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

  • STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more

    STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more

    By Ed Silverman

    Oct. 9, 2026

    Pharmalot Columnist, Senior Writer

    And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, promenade with the official mascots and celebrate the turning of another page on the calendar with our remaining Pharmalot ancestor. We also hope to hold another listening party, where the rotation will likely include this, this, this, this and this. And what about you? This is the time of year when apples and pumpkins grow lonely, waiting for someone to take them to a nice home. So perhaps a drive in the country is in order. This may also be an opportunity to simply enjoy the great outdoors, given the lovely change of scenery that is taking place. Or you could keep busy by strolling city streets and watching life go by. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…

    Argenx disclosed that its blockbuster drug Vyvgart failed to outperform placebo in a Phase 3 trial of patients with Sjögren’s disease, a chronic autoimmune disorder, marking an unusual setback for the company, STAT says. Argenx has racked up a series of wins in autoimmune disorders en route to becoming one of the world’s largest biotechs based on market cap. William Blair analysts had projected $1.4 billion in peak sales from Vyvgart in Sjögren’s disease but described the trial as high risk, in part because Sjögren’s patients often have high placebo responses. The trial was supposed to be completed next year, but it was stopped early after a data monitoring committee determined the primary endpoint would not be met.

    The Food and Drug Administration flagged a potential safety signal after four deaths were reported among patients with treatment-resistant schizophrenia who received investigational evenamide in clinical trials, MedPage Today informs us. In April, the agency halted patient enrollment in a Phase 3 trial for the Newron Pharmaceuticals medicine after the sudden death of a participant. That hold remains in place at U.S. study centers but enrollment continues in other countries, and additional clinical sites are being added. The FDA concern relates to the risk that some sodium channel blockers may trigger arrhythmias that can lead to serious cardiovascular events or seizures.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe